Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

BACKGROUND: There is limited evidence in the literature on the long-term effectiveness and cost-effectiveness of treatments for Acute Severe Ulcerative Colitis (ASUC). The study aimed to perform decision analytic model-based long-term cost-utility analysis (CUA) of infliximab versus ciclosporin for...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Mohammed Fasihul, Longo, Mirella, Cohen, David, Groves, Sam, Alrubaiy, Laith, Hutchings, Hayley A., Watkins, Alan, Sebastain, Shaji, Williams, John G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993375/
https://www.ncbi.nlm.nih.gov/pubmed/36890533
http://dx.doi.org/10.1186/s12913-023-09233-w

Ejemplares similares

Ejemplares similares